The estimated Net Worth of Ivan Bergstein is at least $39.1 millió dollars as of 15 April 2020. Ivan Bergstein owns over 53,618 units of Stemline Therapeutics stock worth over $33,175,295 and over the last 11 years Ivan sold STML stock worth over $5,891,527.
Sign up
Ivan Bergstein STML stock SEC Form 4 insiders trading
Ivan has made over 24 trades of the Stemline Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Ivan sold 53,618 units of STML stock worth $261,656 on 15 April 2020.
The largest trade Ivan's ever made was selling 57,451 units of Stemline Therapeutics stock on 9 March 2020 worth over $286,106. On average, Ivan trades about 16,034 units every 60 days since 2013. As of 15 April 2020 Ivan still owns at least 2,804,336 units of Stemline Therapeutics stock.
You can see the complete history of Ivan Bergstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Ivan Bergstein's mailing address?
Ivan's mailing address filed with the SEC is C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, ELEVENTH FLOOR, NEW YORK, NY, 10022.
Insiders trading at Stemline Therapeutics
Over the last 12 years, insiders at Stemline Therapeutics have traded over $12,490,046 worth of Stemline Therapeutics stock and bought 10,500 units worth $128,270 . The most active insiders traders include Eric Dobmeier, Kenneth Hoberman és Ivan Bergstein. On average, Stemline Therapeutics executives and independent directors trade stock every 29 days with the average trade being worth of $169,110. The most recent stock trade was executed by Robert Francomano on 4 May 2020, trading 272 units of STML stock currently worth $3,131.
What does Stemline Therapeutics do?
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
What does Stemline Therapeutics's logo look like?
Complete history of Ivan Bergstein stock trades at Stemline Therapeutics
Stemline Therapeutics executives and stock owners
Stemline Therapeutics executives and other stock owners filed with the SEC include:
-
Eric Dobmeier,
Director -
Ron Bentsur,
Director -
Alan S Forman,
Director -
Kenneth Hoberman,
Chief Operating Officer -
Kenneth J Zuerblis,
Director -
David Gionco,
Chief Accounting Officer -
J Kevin Buchi,
Director -
Eric K Rowinsky,
Chief Medical Officer -
Ivan Bergstein,
Chief Executive Officer -
Robert Francomano,
Chief Commercial Officer -
Mark Sard,
Director -
Daniel Hume,
Director -
Darren S Cline,
Director -
Stephen P Hall,
Chief Accounting Officer